MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
MCE 国际站:PI3K/Akt/mTOR Compound Library
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.MCE owns a unique collection of 528 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
Description & Advantages:
• A unique collection of 528 small molecule inhibitors used for PI3K/Akt/mTOR pathway research.
• Targets such as Akt, AMPK, DNA-PK, PDK-1, mTOR, PI3K, PTEN, etc.
• A valuable tool for studying PI3K/Akt/mTOR-related survival, proliferation, and apoptosis of cells and related diseases.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by the FDA.
• Structurally diverse, medicinally active, and cell permeable.
• Rich documentation with structure, IC50, and summary.
• NMR and HPLC validated to ensure high purity.
• All compounds are in stock and continuously updated.